Difference between revisions of "Lapuleucel-T (DN24-02)"
Warner-admin (talk | contribs) |
m |
||
| (11 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Autologous cellular immunotherapy, designed to stimulate a response against HER2/Neu receptor. Autologous peripheral blood mononuclear cells, which include antigen presenting cells (APCs), are obtained via leukapheresis. They are then activated ex vivo with a recombinant fusion protein.<ref>[ | + | Class/mechanism: Autologous cellular immunotherapy, designed to stimulate a response against HER2/Neu receptor. Autologous peripheral blood mononuclear cells, which include antigen presenting cells (APCs), are obtained via leukapheresis. They are then activated ex vivo with a recombinant fusion protein.<ref>[https://clinicaltrials.gov/study/NCT01353222 NCT01353222]</ref><ref>[http://www.dendreon.com/researchdevelopment/ACIproductcandidate/ DN24-02 manufacturer's website]</ref> |
Route: IV | Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. |
| − | |||
| − | |||
| − | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' DN24-02 | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | |||
| − | |||
[[Category:Cellular therapy]] | [[Category:Cellular therapy]] | ||
| − | [[Category: | + | [[Category:Intravenous medications]] |
| − | |||
| − | [[Category: | + | [[Category:Urothelial carcinoma medications (investigational)]] |
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 19:22, 9 September 2023
General information
Class/mechanism: Autologous cellular immunotherapy, designed to stimulate a response against HER2/Neu receptor. Autologous peripheral blood mononuclear cells, which include antigen presenting cells (APCs), are obtained via leukapheresis. They are then activated ex vivo with a recombinant fusion protein.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Also known as
- Code name: DN24-02